VIA
TCRT icon

Vident Investment Advisory’s Alaunos Therapeutics TCRT Stock Holding History

Vident Investment Advisory’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,925
Closed -$707K – 885
2020
Q1 		$707K Sell
1,925
-120
-6% -$62.1K 0.05% 489
2019
Q4 		$1.45M Buy
2,045
+239
+13% +$164K 0.09% 339
2019
Q3 		$1.16M Sell
1,806
-51
-3% -$40.5K 0.1% 155
2019
Q2 		$1.62M Buy
+1,857
New +$1.28M 0.13% 107
2018
Q4 		– Sell
-3,670
Closed -$1.76M – 915
2018
Q3 		$1.76M Sell
3,670
-245
-6% -$105K 0.07% 352
2018
Q2 		$1.77M Buy
3,915
+1,248
+47% +$791K 0.07% 335
2018
Q1 		$1.74M Buy
2,667
+713
+36% +$444K 0.07% 330
2017
Q4 		$1.21M Buy
1,954
+546
+39% +$392K 0.05% 351
2017
Q3 		$1.3M Buy
1,408
+43
+3% +$38.2K 0.07% 332
2017
Q2 		$1.27M Buy
1,365
+445
+48% +$436K 0.11% 296
2017
Q1 		$875K Buy
920
+153
+20% +$142K 0.09% 315
2016
Q4 		$615K Buy
767
+42
+6% +$37.9K 0.07% 327
2016
Q3 		$612K Sell
725
-23
-3% -$18.5K 0.08% 324
2016
Q2 		$616K Sell
748
-244
-25% -$266K 0.09% 354
2016
Q1 		$1.1K Buy
992
+475
+92% +$486K 0.07% 349
2015
Q4 		$645K Buy
+517
New +$855K 0.08% 350

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vident Investment Advisory's TCRT Position: Q2 2020 in Review

Vident Investment Advisory sold out of Alaunos Therapeutics (TCRT) in Q2 2020, closing a stake of 1,925 shares — an estimated $707K sold.

Vident Investment Advisory first reported a position in TCRT in Q4 2015 and held it in 16 quarters. The position peaked at $1.77M in Q2 2018. 146 funds tracked by Wall St. Rank hold TCRT as of Q2 2020.

  • Vident Investment Advisory reported no remaining Alaunos Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Vident Investment Advisory sold 1,925 Alaunos Therapeutics shares in Q2 2020, an estimated $707K.
  • Vident Investment Advisory first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 16 quarters.
  • Vident Investment Advisory's Alaunos Therapeutics position peaked at $1.77M in Q2 2018.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2020.

Based on Vident Investment Advisory's 13F filing for Q2 2020, filed 17 Jul 2020.